Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGN NYSE:CO NYSE:CORBF NASDAQ:MRAI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$16.22+0.5%$12.76$9.22▼$21.00$746.33M1821,734 shs1.41 million shsCOGlobal Cord Blood$1.05-40.0%$1.04$2.03▼$5.50$127.63M0.16216,519 shs11,455 shsCORBFGlobal Cord Blood$1.05-40.0%$1.03$0.25▼$1.75$127.63M-0.692,256 shs11,455 shsMRAIMarpai$1.38+0.4%$1.35$0.42▼$1.68$23.83M4.6617,614 shs7,940 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen-0.43%+3.73%+24.25%+48.07%+26.99%COGlobal Cord Blood+9.37%+25.00%+146.48%+75.00%+45.83%CORBFGlobal Cord Blood-40.00%-30.00%+47.89%+5.00%-12.50%MRAIMarpai-1.08%-1.79%+4.96%+1.85%+186.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXGNAxoGen2.4655 of 5 stars3.52.00.00.02.61.70.6COGlobal Cord BloodN/AN/AN/AN/AN/AN/AN/AN/ACORBFGlobal Cord BloodN/AN/AN/AN/AN/AN/AN/AN/AMRAIMarpaiN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 3.00Buy$26.0060.30% UpsideCOGlobal Cord Blood 0.00N/AN/AN/ACORBFGlobal Cord Blood 0.00N/AN/AN/AMRAIMarpai 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$203.27M3.67N/AN/A$2.44 per share6.65COGlobal Cord Blood$1.24B0.10$0.25 per share4.19$6.34 per share0.17CORBFGlobal Cord Blood$196.12M0.65$0.75 per share1.40N/A∞MRAIMarpai$34.87M0.68N/AN/A($1.72) per share-0.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$9.96M-$0.10N/AN/AN/A-2.29%-4.43%-2.34%11/6/2025 (Estimated)COGlobal Cord Blood$79.04M$0.641.64∞N/AN/AN/AN/AN/ACORBFGlobal Cord Blood$79.04MN/A0.00∞N/AN/AN/AN/AN/AMRAIMarpai-$28.75M-$0.87N/A∞N/A-85.70%N/A-100.23%11/11/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/ACOGlobal Cord Blood$0.087.62%N/A12.50%N/ACORBFGlobal Cord BloodN/AN/AN/AN/AN/AMRAIMarpaiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.594.142.67COGlobal Cord BloodN/AN/AN/ACORBFGlobal Cord BloodN/AN/AN/AMRAIMarpaiN/A0.820.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%COGlobal Cord BloodN/ACORBFGlobal Cord BloodN/AMRAIMarpai49.75%Insider OwnershipCompanyInsider OwnershipAXGNAxoGen2.78%COGlobal Cord Blood0.50%CORBFGlobal Cord Blood0.50%MRAIMarpai46.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45046.01 million44.73 millionOptionableCOGlobal Cord Blood1,202121.55 millionN/ANo DataCORBFGlobal Cord Blood1,200121.55 millionN/ANot OptionableMRAIMarpai15017.27 million5.61 millionNo DataCO, CORBF, MRAI, and AXGN HeadlinesRecent News About These CompaniesMarpai (NASDAQ:MRAI) Stock Price Down 1.1% - Time to Sell?August 28 at 2:48 AM | americanbankingnews.comMarpai, Inc. Reports Significant Q2 2025 TurnaroundAugust 14, 2025 | tipranks.comMarpai, Inc. (MRAI) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | seekingalpha.comMARPAI REPORTS SECOND QUARTER 2025 FINANCIAL RESULTSAugust 13, 2025 | prnewswire.comMARPAI TO HOST WEBCAST ON AUGUST 14, 2025 TO DISCUSS SECOND QUARTER 2025 FINANCIAL RESULTSAugust 7, 2025 | prnewswire.comMARPAIRX REVOLUTIONIZES PHARMACY BENEFITS WITH UNPRECEDENTED TRANSPARENCY AND SAVINGSJuly 24, 2025 | prnewswire.comEarnings call transcript: Marpai posts improved Q1 2025 results amid cost cutsMay 17, 2025 | uk.investing.comMarpai, Inc. Reports Q1 2025 Financial ResultsMay 15, 2025 | tipranks.comMarpai targets cash flow positivity in 2025 with cost reductions and leadership changesMay 15, 2025 | msn.comMarpai, Inc. (MRAI) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comMarpai appoints new COO to accelerate growthMay 15, 2025 | uk.investing.comMARPAI REPORTS FIRST QUARTER 2025 FINANCIAL RESULTSMay 14, 2025 | prnewswire.comMARPAI HIRES DALLAS SCRIP AS CHIEF OPERATING OFFICERMay 13, 2025 | prnewswire.comMarket Access RICI Agriculture UCITS (MRAI)May 8, 2025 | investing.comMARPAI TO HOST WEBCAST ON MAY 15, 2025 TO DISCUSS FIRST QUARTER 2025 FINANCIAL RESULTSMay 7, 2025 | prnewswire.comMarpai, Inc. to Present at the Planet MicroCap Showcase Las VegasApril 15, 2025 | prnewswire.comMarpai targets profitability in 2025 with new initiatives and strategic partnershipsMarch 27, 2025 | msn.comMarpai, Inc. (MRAI) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comMARPAI REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTSMarch 26, 2025 | prnewswire.comMARPAI TO HOST WEBCAST ON MARCH 27, 2025 TO DISCUSS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTSMarch 20, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Stocks Riding the AI Data Center Buildout WaveBy Chris Markoch | August 6, 2025This Drone Stock Is on Sale Despite Big Army ContractBy Jeffrey Neal Johnson | July 31, 20253 AI Infrastructure Stocks Powering the Next Tech RevolutionBy Ryan Hasson | August 8, 2025Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli LillyBy Jordan Chussler | August 9, 2025CO, CORBF, MRAI, and AXGN Company DescriptionsAxoGen NASDAQ:AXGN$16.22 +0.08 (+0.50%) Closing price 04:00 PM EasternExtended Trading$16.52 +0.30 (+1.85%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Global Cord Blood NYSE:CO$1.05 -0.70 (-40.00%) As of 08/27/2025Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants. Global Cord Blood was founded on January 17, 2008 and is headquartered in Hong Kong.Global Cord Blood NYSE:CORBF$1.05 -0.70 (-40.00%) As of 08/27/2025 02:35 PM EasternGlobal Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.Marpai NASDAQ:MRAI$1.38 +0.01 (+0.36%) As of 02:06 PM EasternMarpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, bill review and cost containment services. Marpai, Inc. was incorporated in 2021 and is based in Tampa, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike at a Crossroads: AI Halo vs. Risks NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It NIO Just Got Its Second Upgrade of the Month, and It’s Big As Bitcoin Falls and Ethereum Rallies, Coinbase Stock Comes Back Williams-Sonoma Q2 Results Prove Its Buy-and-Hold Quality Okta: Market Comes to a Boil, Explosive Upside Is Possible MongoDB Roars Back to Life: It’s Not Too Late to Buy More Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access